Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.
Vitasora Health Limited reported a remarkable 226% increase in patient programs and secured an $11 million capital raise, positioning the company for accelerated growth and a path to cash flow breakeven in late 2026.
